Following mind map shows sales forecast for each of the drug
---- {|border="2" cellspacing="0" cellpadding="4" width="100%" align="center"|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF"mm>'''Oncology Drugs'''</font>|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Active Ingredient'''</font>|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Oncology Area'''</font>|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Company'''</font>|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Patent expiry year'''</font>|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''[[Sales (2010) in $ mn'''Forecast Mindmap.mm]]</font>|-|align = "center" bgcolor = "#DCE6F1"|xeloda|align = "center" bgcolor = "#DCE6F1"|capecitabine|align = "center" bgcolor = "#DCE6F1"|Pyrimidine analogue|align = "center" bgcolor = "#DCE6F1"|Roche|align = "center" bgcolor = "#DCE6F1"|Dec-13|align = "center" bgcolor = "#DCE6F1"|510|-|align = "center"|Abraxane|align = "center"|Paclitaxel|align = "center"|Taxane|align = "center"|Celgene|align = "center"|Mar-13|align = "center"|66|-|align = "center" bgcolor = "#DCE6F1"|Biotax|align = "center" bgcolor = "#DCE6F1"|Paclitaxel|align = "center" bgcolor = "#DCE6F1"|Taxane|align = "center" bgcolor = "#DCE6F1"|Hospira|align = "center" bgcolor = "#DCE6F1"|Dec-16|align = "center" bgcolor = "#DCE6F1"|21|-|align = "center"|Temodar/Temodal|align = "center"|Temozolomide|align = "center"|Alkylating agent|align = "center"|Merck & Co|align = "center"|Aug-13|align = "center"|403|-|align = "center" bgcolor = "#DCE6F1"|Vidaza|align = "center" bgcolor = "#DCE6F1"|Azacitidine|align = "center" bgcolor = "#DCE6F1"|DNA methyltransferase (DNMT) inhibitor|align = "center" bgcolor = "#DCE6F1"|Celgene|align = "center" bgcolor = "#DCE6F1"|May-11|align = "center" bgcolor = "#DCE6F1"|270|-|align = "center"|Zoladex|align = "center"|Goserelin|align = "center"|LHRH analogue|align = "center"|AstraZeneca|align = "center"|Nov-11|align = "center"|46|-|}<br clear="all"mm>
==Bibliography==
